Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Dial-in information and webcast details are listed below:
Participant Toll Free Dial-In Number: 888-317-6003
Participant International Dial-In Number: 412-317-6061
Conference ID: 3493752
Callers should dial in approximately 10 minutes before the live call begins.
Dial-in information and webcast details for replay access are listed below. The dial-in replay will be available until
Replay Toll Free Dial-In Number: 877-344-7529
Replay International Dial-In Number: 412-317-0088
Replay Access Code: 10114808
The slide presentation will be available via both the webcast and the presentations page of the investor relations portion of Galectin’s website.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (
Source: Galectin Therapeutics Inc.